Silenseed is a development stage biopharmaceutical company specializing in the development of proprietary RNA interference (RNAi)-based cancer drugs and delivery systems. Their mission is to effectively penetrate and treat malignant solid tumors using their innovative technology. With their second generation drug, siRNA, and the microparticle product SIL-103, Silenseed aims to provide one of the most highly effective treatments for solid tumor cancers.

Focused on the treatment of locally advanced and borderline resectable pancreatic cancer, Silenseed constantly asks themselves, What is the benefit for the patient? To address this, they foster a multi-disciplined approach, encourage direct communication, and strive for innovation. Their dedication extends not only to their team but also to maintaining professional and personal relationships with all project participants. Silenseed values fairness, encouragement, dedication, diligence, and commitment.

They believe in their people and their enthusiasm, dedication, commitment, and capabilities. As a company, they are committed to making a positive impact in the field of cancer treatment. For more information, please visit the Silenseed website